What's new — Retinoblastoma
Generated 2026-11-01 from the publication dates of every paper cited in this condition's pages.
This page answers a different question from the curation log. The log says when we last edited a
page; this says how recent the evidence on those pages is — so you can tell settled ground from a
field that is actively moving, and jump straight to what has emerged lately.
How much of this condition's evidence is recent
| Published within |
Cited papers |
| last week |
0 |
| last month |
0 |
| last 2 months |
4 |
| last 3 months |
5 |
| last 6 months |
7 |
| last year |
19 |
| older than a year |
354 |
Counts are cumulative: a paper from last week also counts inside "last month". Dates are PubMed
publication or e-publication dates, so a paper may have appeared online before its journal issue.
Newest evidence first
The most recent cited papers, with the pages that use them.
| Published |
Paper |
Cited on |
| 2026-10-01 |
Multi-institutional study evaluating the role of liquid biopsy to determine risk of extraocular disease, therapy response and recurrence in retinoblastoma — Clin Cancer Res ([PMID 42873577](https://pubmed.ncbi.nlm.nih.gov/42873577/){target="_blank" rel="noopener"}) |
extraocular-metastatic-and-trilateral-disease, molecular-pathogenesis-and-cell-of-origin |
| 2026-10-01 |
Proton Radiotherapy Decreases Incidence of Radiation-Induced Second Malignant Neoplasms Compared to Photon Radiotherapy in Patients With Retinoblastoma — Pediatr Blood Cancer ([PMID 42861579](https://pubmed.ncbi.nlm.nih.gov/42861579/){target="_blank" rel="noopener"}) |
second-cancers-and-survivorship |
| 2026-09-02 |
Global retinoblastoma service availability in 2024 and equity trends since 2017 — Br J Ophthalmol ([PMID 42463304](https://pubmed.ncbi.nlm.nih.gov/42463304/){target="_blank" rel="noopener"}) |
global-access-and-outcome-disparity, systemic-chemotherapy |
| 2026-09-01 |
Risk of subsequent primary melanoma in 68 002 five-year survivors of childhood and adolescent cancer in Europe: the PanCareSurFup cohort study — J Natl Cancer Inst ([PMID 41915055](https://pubmed.ncbi.nlm.nih.gov/41915055/){target="_blank" rel="noopener"}) |
second-cancers-and-survivorship |
| 2026-08-03 |
Intra-arterial chemotherapy for retinoblastoma: a structured narrative review — World J Pediatr Surg ([PMID 42553724](https://pubmed.ncbi.nlm.nih.gov/42553724/){target="_blank" rel="noopener"}) |
intra-arterial-chemotherapy |
| 2026-07-03 |
Multimodal Imaging of Optic Nerve Invasion in Unilateral Retinoblastoma — Ophthalmology ([PMID 42397330](https://pubmed.ncbi.nlm.nih.gov/42397330/){target="_blank" rel="noopener"}) |
enucleation-and-high-risk-pathology |
| 2026-07-02 |
Retinoblastoma presenting as congenital glaucoma — BMJ Case Rep ([PMID 42486661](https://pubmed.ncbi.nlm.nih.gov/42486661/){target="_blank" rel="noopener"}) |
classification-and-staging |
| 2026-05-01 |
Abemaciclib Inhibits Retinoblastoma Tumor Growth by Targeting CDK1/2 — Invest Ophthalmol Vis Sci ([PMID 42212883](https://pubmed.ncbi.nlm.nih.gov/42212883/){target="_blank" rel="noopener"}) |
molecular-pathogenesis-and-cell-of-origin |
| 2026-03-01 |
Correction: Practical guidelines on imaging of retinoblastoma: a 2025 update on behalf of the European Retinoblastoma Imaging Collaboration and the European Retinoblastoma Group — Eur Radiol ([PMID 40932489](https://pubmed.ncbi.nlm.nih.gov/40932489/){target="_blank" rel="noopener"}) |
guidelines |
| 2026-02-06 |
Internalized stigma among pediatric patients with osteosarcoma and retinoblastoma in Guatemala, Jordan, and Zimbabwe — Front Oncol ([PMID 41727643](https://pubmed.ncbi.nlm.nih.gov/41727643/){target="_blank" rel="noopener"}) |
vision-outcomes-and-patient-experience |
| 2026-02-01 |
Intravenous chemotherapy versus intra-arterial chemotherapy for retinoblastoma — Cochrane Database Syst Rev ([PMID 41700592](https://pubmed.ncbi.nlm.nih.gov/41700592/){target="_blank" rel="noopener"}) |
intra-arterial-chemotherapy |
| 2026-01-01 |
A bird's eye view on potential molecular prognostic markers in retinoblastoma: insights for precision oncology — Ophthalmic Genet ([PMID 41542805](https://pubmed.ncbi.nlm.nih.gov/41542805/){target="_blank" rel="noopener"}) |
intravitreal-and-intracameral-chemotherapy, molecular-pathogenesis-and-cell-of-origin |
| 2026-01-01 |
The utility of aqueous humor liquid biopsy in retinoblastoma genetic analysis: a systematic review of concordance and influencing factors — Ophthalmic Genet ([PMID 41521223](https://pubmed.ncbi.nlm.nih.gov/41521223/){target="_blank" rel="noopener"}) |
intravitreal-and-intracameral-chemotherapy, molecular-pathogenesis-and-cell-of-origin |
| 2025-12-02 |
Adjuvant Chemotherapy in Retinoblastoma with Postlaminar Optic Nerve Invasion: A Global Multicenter Study — Ophthalmol Retina ([PMID 41475682](https://pubmed.ncbi.nlm.nih.gov/41475682/){target="_blank" rel="noopener"}) |
enucleation-and-high-risk-pathology |
| 2025-12-01 |
Retinoblastoma management in China: clinical challenges — Int J Ophthalmol ([PMID 41280625](https://pubmed.ncbi.nlm.nih.gov/41280625/){target="_blank" rel="noopener"}) |
clinical-presentation-and-diagnosis, global-access-and-outcome-disparity, red-flags-and-safety-concerns, vision-outcomes-and-patient-experience |
| 2025-11-11 |
[The efficacy of topotecan versus topotecan combined with melphalan in the treatment of vitreous seeds in retinoblastoma] — Zhonghua Yan Ke Za Zhi ([PMID 41218901](https://pubmed.ncbi.nlm.nih.gov/41218901/){target="_blank" rel="noopener"}) |
intravitreal-and-intracameral-chemotherapy |
| 2025-11-03 |
GD2-CAR-Engineered Microglia Exhibit Antitumor Effects in Organoids and Animal Models of Retinoblastoma — Invest Ophthalmol Vis Sci ([PMID 41230904](https://pubmed.ncbi.nlm.nih.gov/41230904/){target="_blank" rel="noopener"}) |
vision-outcomes-and-patient-experience |
| 2025-11-02 |
Diffuse infiltrating retinoblastoma: a multicentre, international, data-sharing study — Br J Ophthalmol ([PMID 40738737](https://pubmed.ncbi.nlm.nih.gov/40738737/){target="_blank" rel="noopener"}) |
classification-and-staging, systemic-chemotherapy |
| 2025-11-01 |
Orbital myiasis in neglected orbital retinoblastoma — Natl Med J India ([PMID 41645972](https://pubmed.ncbi.nlm.nih.gov/41645972/){target="_blank" rel="noopener"}) |
clinical-presentation-and-diagnosis, global-access-and-outcome-disparity, red-flags-and-safety-concerns |
Trials — what has moved
20 registered trials are cited by this condition's pages. Registry records were re-checked live when this page was generated, so status, enrolment and results-posting below reflect ClinicalTrials.gov as of that date.
| Registry activity |
Trials |
| trial records updated in the last week |
0 |
| trial records updated in the last month |
1 |
| trial records updated in the last 2 months |
1 |
| trial records updated in the last 3 months |
2 |
| trial records updated in the last 6 months |
5 |
| trial records updated in the last year |
9 |
Recently updated registrations
Posted efficacy and safety results
Trials whose sponsors have posted results to the registry. Adverse-event figures are participant counts summed across all arms as reported — read them against enrolment, and follow the registry link for the arm-by-arm breakdown that determines whether a signal is real.
17 of these trials are still recruiting or active — see the condition's clinical trials page for the full landscape.
Which pages rest on the newest evidence
🔥 marks a page citing three or more papers from the last year — the pages worth re-reading if you
have been away.
Recency is not quality: an old paper may be the definitive one, and a new paper may not replicate.
Use this to find movement, not to rank evidence. See open questions for what
remains unresolved, and the curation log for when these pages were last revised.